Table 2.
Indication for laboratory assessment of DOAC level.
| Overall N = 119 | Apixaban n = 62 | Rivaroxaban n = 57 | |
|---|---|---|---|
| Urgent/emergent procedure | 38 (32) | 28 (45) | 10 (18) |
| Acute kidney injury | 17 (14) | 10 (16) | 7 (12) |
| Bleed event on DOAC | 11 (9) | 5 (8) | 6 (11) |
| Recurrent VTE on DOAC | 10 (8) | 5 (8) | 5 (9) |
| Thrombophilia | 9 (8) | 0 (0) | 9 (16) |
| Other | 7 (6) | 2 (3) | 5 (9) |
| History of recurrent VTE pre-DOAC | 6 (5) | 0 (0) | 6 (11) |
| High body weight | 16 (13) | 10 (16) | 6 (11) |
| Low body weight | 5 (4) | 2 (3) | 3 (5) |